Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
inflammatory myopathy |
| gptkbp:affects |
gptkb:skin
children muscles |
| gptkbp:autoantibody |
gptkb:anti-p155/140
gptkb:anti-MDA5 gptkb:anti-Mi-2 gptkb:anti-NXP2 |
| gptkbp:cause |
unknown
|
| gptkbp:complication |
lipodystrophy
contractures calcinosis vasculopathy |
| gptkbp:diagnosedBy |
gptkb:EMG
MRI muscle biopsy blood tests |
| gptkbp:firstDescribed |
1891
|
| gptkbp:gender |
more common in females
|
| https://www.w3.org/2000/01/rdf-schema#label |
juvenile dermatomyositis
|
| gptkbp:ICD-10_code |
gptkb:M33.0
|
| gptkbp:parent |
gptkb:dermatomyositis
idiopathic inflammatory myopathy |
| gptkbp:prevalence |
rare
2-4 per million children per year |
| gptkbp:prognosis |
variable
improved with early treatment |
| gptkbp:riskFactor |
genetic predisposition
environmental triggers |
| gptkbp:signature |
gptkb:Gottron's_papules
gptkb:V-sign gptkb:shawl_sign heliotrope rash nailfold capillary changes periorbital edema proximal muscle weakness |
| gptkbp:symptom |
fatigue
joint pain muscle weakness skin rash dysphagia calcinosis |
| gptkbp:treatment |
gptkb:methotrexate
gptkb:IVIG physical therapy corticosteroids immunosuppressive drugs |
| gptkbp:bfsParent |
gptkb:dermatomyositis
|
| gptkbp:bfsLayer |
5
|